Search Everything in One Place

Explore the web, images, videos, news, and more – all in one place.

Sports

MLB insider reveals major Adley Rutschman trade update for Baltimore Orioles

MLB Insider Reveals Major Adley Rutschman Trade Update for Baltimore Orioles
MLB Insider Reveals Major Adley Rutschman Trade Update for Baltimore Orioles

The Baltimore Orioles received a major update on Adley Rutschman’s future after an MLB insider shed new light on the […]

The Baltimore Orioles received a major update on Adley Rutschman’s future after an MLB insider shed new light on the team’s trade plans. The latest report offers a clearer picture of Baltimore’s stance as speculation surrounding the All-Star catcher continues to grow ahead of the MLB trade deadline.

MLB Insider Shares New Adley Rutschman Trade Update

Baltimore is in the thick of the AL Wild Card hunt, sitting three games back of the final spot. Despite the rise in performance ahead of the MLB trade deadline, Rutschman has been involved in trade rumors. Will the Orioles trade their All-Star catcher? With a trip to the injured list before the deadline, the odds have dropped.

Rutschman’s injury, combined with Baltimore’s surge, has reduced the already low odds of the team trading him, as reported by The Athletic’s Ken Rosenthal. Rutschman’s contract runs through the 2027 MLB season, and the Orioles were already unlikely to move their franchise catcher.

Due to the injury and the lack of extension, Rutschman’s future with the Orioles will remain uncertain. After all, Baltimore had no problem signing starting pitcher Kyle Bradish to a five-year, $90 million contract extension. Unless president of baseball operations Mike Elias changes his mind, Rutschman could be here to stay in 2026.

What the Update Means for the Baltimore Orioles

Adley Rutschman, Baltimore Orioles
Jun 18, 2026; Seattle, Washington, USA; Baltimore Orioles designated hitter Adley Rutschman (35) reacts following a strikeout looking against the Seattle Mariners during the seventh inning at T-Mobile Park. Mandatory Credit: Joe Nicholson-Imagn Images Credit: IMAGN IMAGES via Reuters Connect

If the Orioles don’t plan on trading Rutschman, it means they should go “all-in” on making the MLB Postseason. After struggling during the 2026 season, Baltimore sold at the MLB trade deadline. In 2026, the Orioles should go in the opposite direction by adding players to the organization.

Instead of trading Taylor Ward, the Orioles should add to their bullpen, which is the biggest need for the roster. Ryan Helsley and Felix Bautista aren’t available for Baltimore, leaving the team without a sure-fire closer. Andrew Kittredge and Tyler Wells have stepped into the role, but the results haven’t been fantastic.

The lineup has been strong, so there aren’t many holes outside of a potential upgrade in the outfield. The Orioles’ main focus should be the bullpen, as it ranks below average in ERA. It has to be the biggest priority for the organization if it wants to return to the MLB postseason during the 2026 season.

Unfortunately for the Orioles, this new update also makes their situation with Rutschman even more uncertain. This was the best opportunity for the Orioles to maximize value if they won’t extend the 28-year-old catcher. With one more year under contract, a potential return will diminish during the 2026 MLB offseason.

What’s Next for Adley Rutschman and the Orioles?

While the latest insider report offers a clearer picture of Baltimore’s current thinking, the trade deadline still leaves time for new developments. If the Orioles receive a significant offer or their deadline strategy changes, speculation surrounding Rutschman’s future could continue. Until then, the 28-year-old catcher should be expected to stay in Baltimore for the rest of the season.

Should the Orioles trade Adley Rutschman, or should Baltimore keep building around him?

Read More: MLB Insider Reveals Detroit Tigers’ Surprising Trade Deadline Plan for Tarik Skubal

Want to see more exclusive sports content like this? Follow Sportsnaut on MSN.

Read full story on Sportsnaut

Related News

More stories you might be interested in.

Factbox-what we know of weight-loss drugs’ pricing, availability as Novo sues Lilly
Reuters·1 hour ago

Factbox-what we know of weight-loss drugs’ pricing, availability as Novo sues Lilly

July 21 (Reuters) - Novo Nordisk accused Eli Lilly of falsely claiming that its weight-loss medicines are more effective, in a U.S. lawsuit, escalating a rivalry between the leaders of the lucrative obesity drug market. The U.S. Centers for Medicare & Medicaid Services this month launched a pilot that initiated broader access to Novo and Lilly's popular GLP-1 drugs as weight-loss treatments at

Top